Get the Stockscreener App
27.27
2.91%
0.77
After Hours:
27.57
0.30
+1.10%
Alumis Inc stock is traded at $27.27, with a volume of 1.40M.
It is up +2.91% in the last 24 hours and up +43.07% over the past month.
Alumis Inc is a clinical-stage biopharmaceutical company with an initial focus on developing its two Tyrosine Kinase 2 ("TYK2") inhibitors: envudeucitinib ("envu"), an allosteric TYK2 inhibitor for the treatment of PsO and SLE; and A-005, a central nervous system ("CNS") penetrant allosteric TYK2 inhibitor, to offer the therapeutic benefit of TYK2 inhibition within the CNS for a broad range of neuroinflammatory and neurodegenerative diseases.
See More
Previous Close:
$26.50
Open:
$26.34
24h Volume:
1.40M
Relative Volume:
1.03
Market Cap:
$3.48B
Revenue:
$8.40M
Net Income/Loss:
$-237.42M
P/E Ratio:
-14.19
EPS:
-1.9213
Net Cash Flow:
$-377.03M
1W Performance:
+0.48%
1M Performance:
+43.07%
6M Performance:
+68.02%
1Y Performance:
+702.06%
1-Day Range:
$25.95
$28.11
1-Week Range:
$25.48
$28.65
52-Week Range:
$3.20
$30.60
Alumis Inc Stock (ALMS) Company Profile
Name
Alumis Inc
Sector
Industry
Phone
650-231-6625
Address
280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO
Compare ALMS vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALMS
Alumis Inc
|
27.27 | 3.59B | 8.40M | -237.42M | -377.03M | -1.9213 |
VRTX
Vertex Pharmaceuticals Inc
|
529.59 | 126.07B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
649.81 | 65.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
916.80 | 57.70B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
313.04 | 40.19B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
189.99 | 39.82B | 742.00K | -1.37B | -1.07B | -7.0731 |
Alumis Inc Stock (ALMS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-11-26 | Initiated | Raymond James | Strong Buy |
| Feb-25-26 | Initiated | Stifel | Buy |
| Jan-21-26 | Initiated | Chardan Capital Markets | Buy |
| Jul-25-25 | Initiated | Wells Fargo | Overweight |
| Jun-10-25 | Resumed | Guggenheim | Buy |
| Jan-30-25 | Initiated | Oppenheimer | Outperform |
| Oct-31-24 | Initiated | Robert W. Baird | Outperform |
| Oct-17-24 | Initiated | H.C. Wainwright | Buy |
| Jul-23-24 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-23-24 | Initiated | Guggenheim | Buy |
| Jul-23-24 | Initiated | Leerink Partners | Outperform |
| Jul-23-24 | Initiated | Morgan Stanley | Overweight |
View All
Alumis Inc Stock (ALMS) Latest News
Stifel and Guggenheim Stay Bullish on Alumis (ALMS) - Insider Monkey
Enterprise value to EBITDA forward of Alumis Inc. – NASDAQ:ALMS - TradingView
Enterprise value to revenue forward of Alumis Inc. – NASDAQ:ALMS - TradingView
Alumis Inc.(NasdaqGS: ALMS) added to Russell 2500 Growth Benchmark - marketscreener.com
Alumis Inc.(NasdaqGS: ALMS) dropped from Russell Microcap Value Benchmark Index - marketscreener.com
Alumis Unveils Breakthrough TYK2 Inhibitors: Leading Clinical Results in Psoriasis and Lupus, $180B+ Market Opportunity by 2030 318 – Minichart - Minichart
Alumis Inc.(NasdaqGS: ALMS) dropped from Russell 2000 Value Benchmark - marketscreener.com
Alumis updates corporate presentation highlighting envudeucitinib Phase 3 wins, SLE and NDA timing - TradingView
Alumis (NASDAQ: ALMS) posts updated June 2026 corporate presentation - Stock Titan
Alumis Inc.(NasdaqGS: ALMS) added to Russell 2000 Growth Benchmark - marketscreener.com
Alumis (ALMS) Is Up 7.3% After Russell Reclassifies It Into Growth Indices What’s Changed - simplywall.st
Oppenheimer Maintains Alumis(ALMS.US) With Buy Rating, Maintains Target Price $55 - Moomoo
Alumis: Is Envudeucitinib The 'Real Deal?' We Should Find Out Soon - Seeking Alpha
Alumis Inc. Actuals & Estimates (BOATS:ALMS) - TradingView
ALMS Forecast — Price Target — Prediction for 2027 - TradingView
Alumis | 4: Statement of changes in beneficial ownership of securities-10% Owner Foresite Capital Management VI LLC - Moomoo
Alumis Inc (ALMS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Alumis Inc (ALMS) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Alumis Inc (ALMS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Alumis Inc (ALMS) Valuation: PE, PB & Fair Value Analysis - TradingKey
Alumis Inc (ALMS) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Alumis Inc (ALMS) Institutional Confidence - TradingKey
ALMS Q1 2026 Earnings: Narrower-than-Expected Loss Lifts SharesROIC Trend Report - dars.gov.et
Alumis Inc (ALMS) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Alumis Inc (ALMS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Alumis Inc (ALMS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Alumis Stock Sinks As Revenue Shock Jolts Hopes - TipRanks
ALMS Q1 2026 Earnings: EPS Beat Drives 15.55% Stock SurgeRevenue Warning Signal - newsline.com
Alumis | ARS: Annual Report to Security Holders - Moomoo
Alumis (ALMS) Sees 10.3% Surge, Reaching $23.06 - GuruFocus
ALUMIS INC (ALMS) Stock Chart - ChartMill
Alumis Shares Surge 16% as Traders Eye New Drug Move - TechStock²
Why Alumis Inc. Shares Are Suddenly Climbing - TipRanks
ALMS Q1 2026 Earnings: Narrower-Than-Expected Loss Propels Stock HigherMargin Compression Risk - newsline.com
Alumis | SCHEDULE 13D/A: Others - Moomoo
ACT CAPITAL MANAGEMENT, LLC's Alumis Inc(ALMS) Holding History - GuruFocus
Why Alumis Inc. Stock Is Sinking So Sharply - TipRanks
ALMS Q1 2026 Earnings: EPS Surprises to the Upside Amid Pre-Revenue Clinical StagePre-Earnings Drift - newsline.com
Has Alumis's Envudeucitinib Redefined Psoriasis Treatment - Kavout
Analyst Sentiment On Alumis (ALMS) Remains Strong Following Q1 Results And Envudeucitinib Pipeline Advancements - Insider Monkey
ALMS Q1 2026 Earnings: EPS Beat Partially Offsets Investor ConcernsProfit Cycle Analysis - The Legal Advocate
Alumis (ALMS) Chief Medical Officer exercises stock options for 26,852 shares - Stock Titan
ALMSAlumis Inc Stock Price and Quote - Finviz
10 Under-the-Radar Stocks with Massive Upside for 2026 - Insider Monkey
TOWERVIEW LLC's Alumis Inc(ALMS) Holding History - GuruFocus
Alumis Inc. (ALMS) Q1 2026 Earnings: Narrower Loss Mirrors Operational Discipline, Pre-Revenue Stage PersistsEPS Guidance Update - The Legal Advocate
Alumis Inc. (ALMS) Edges Lower, Consolidating Above Key Support LevelWyckoff Distribution - newsline.com
How Alumis’ Revenue Slide but Smaller Per-Share Loss Will Impact Alumis (ALMS) Investors - simplywall.st
Alumis | S-3ASR: Automatic shelf registration statement of securities of well-known seasoned issuers - Moomoo
Alumis Analyst Ratings and Price Targets | NASDAQ:ALMS - Benzinga
Is Alumis (ALMS) Trading Short-Term Revenue for a Leaner, More Focused Business Model? - Yahoo Finance
Alumis Inc Stock (ALMS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Alumis Inc Stock (ALMS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| AKKARAJU SRINIVAS | Director |
Jan 09 '26 |
Buy |
17.00 |
588,235 |
9,999,995 |
1,853,488 |
| Foresite Labs, LLC | 10% Owner |
Jan 08 '26 |
Buy |
17.00 |
411,764 |
6,999,988 |
5,702,536 |
| Foresite Capital Management VI | 10% Owner |
Jan 08 '26 |
Buy |
17.00 |
411,764 |
6,999,988 |
5,702,536 |
| Tananbaum James B. | Director |
Jan 08 '26 |
Buy |
17.00 |
411,764 |
6,999,988 |
5,702,536 |
| AKKARAJU SRINIVAS | Director |
Dec 05 '25 |
Buy |
9.84 |
186,377 |
1,833,760 |
1,265,253 |
| AKKARAJU SRINIVAS | Director |
Dec 03 '25 |
Buy |
7.75 |
100,000 |
775,000 |
1,012,849 |
| AKKARAJU SRINIVAS | Director |
Dec 02 '25 |
Buy |
7.55 |
96,000 |
724,800 |
912,849 |
| AKKARAJU SRINIVAS | Director |
Dec 04 '25 |
Buy |
8.18 |
66,027 |
540,101 |
1,078,876 |
| AKKARAJU SRINIVAS | Director |
Dec 01 '25 |
Buy |
7.46 |
86,350 |
644,171 |
816,849 |
| AKKARAJU SRINIVAS | Director |
Nov 26 '25 |
Buy |
7.64 |
48,537 |
370,823 |
691,797 |
0.05%
0.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):